Bank of New York Mellon’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-6,931
| Closed | -$120K | – | 4271 |
|
|
2024
Q1 | $120K | Sell |
6,931
-1,981
| -22% | -$34.4K | ﹤0.01% | 4007 |
|
|
2023
Q4 | $139K | Buy |
8,912
+1,619
| +22% | +$25.3K | ﹤0.01% | 4024 |
|
|
2023
Q3 | $361K | Buy |
7,293
+576
| +9% | +$28.5K | ﹤0.01% | 3719 |
|
|
2023
Q2 | $525K | Buy |
6,717
+1,587
| +31% | +$124K | ﹤0.01% | 3559 |
|
|
2023
Q1 | $465K | Buy |
5,130
+375
| +8% | +$34K | ﹤0.01% | 3524 |
|
|
2022
Q4 | $561K | Sell |
4,755
-3
| -0.1% | -$354 | ﹤0.01% | 3484 |
|
|
2022
Q3 | $862K | Buy |
4,758
+708
| +17% | +$128K | ﹤0.01% | 3279 |
|
|
2022
Q2 | $364K | Buy |
4,050
+220
| +6% | +$19.8K | ﹤0.01% | 3777 |
|
|
2022
Q1 | $594K | Hold |
3,830
| – | – | ﹤0.01% | 3610 |
|
|
2021
Q4 | $1.14M | Hold |
3,830
| – | – | ﹤0.01% | 3309 |
|
|
2021
Q3 | $2.21M | Buy |
3,830
+566
| +17% | +$326K | ﹤0.01% | 2928 |
|
|
2021
Q2 | $1.48M | Sell |
3,264
-395
| -11% | -$179K | ﹤0.01% | 3185 |
|
|
2021
Q1 | $1.97M | Buy |
3,659
+721
| +25% | +$388K | ﹤0.01% | 2932 |
|
|
2020
Q4 | $2.6M | Buy |
2,938
+647
| +28% | +$572K | ﹤0.01% | 2685 |
|
|
2020
Q3 | $1.45M | Buy |
+2,291
| New | +$1.45M | ﹤0.01% | 2879 |
|